This research seeks blood-based biomarkers that predict which people infected with Chagas disease will later develop life-threatening cardiomyopathy. By analysing immune proteins in blood samples from Bolivia, it aims to enable earlier diagnosis, targeted monitoring, and preventative treatment, offering a model for predicting and preventing many chronic diseases before irreversible damage occurs.

This research investigates a new targeted treatment strategy for kidney cancer by inhibiting the cancer-promoting protein PIM1 while enhancing TRAIL-mediated apoptosis. Together with the FDA-approved drug ONC201, this combination restores cancer cells' ability to self-destruct, offering a promising therapeutic approach now being evaluated in preclinical studies.

This research identifies UCH-L1 as a promising blood biomarker directly linked to human eggs, offering a new way to measure ovarian reserve. A simple blood test could improve fertility assessment, detect premature ovarian aging earlier, and provide valuable insights into broader aspects of women's health, including cardiovascular health, cognitive aging, and longevity.

This study introduces a “brain stress test” for depression, combining targeted brain stimulation with neuroimaging. Depressed individuals show exaggerated brain responses, which increase with repeated episodes. The test may serve as an early warning signal, helping clinicians identify relapse risk and intervene before depression returns.

Psychiatric symptoms often precede neurodegenerative diseases, but the biological link remains unclear. This research examines the FMR1 gene using postmortem brain tissue to uncover shared molecular mechanisms, aiming to predict neurodegeneration earlier, improve treatment strategies, and reframe psychiatric symptoms as potential early warning signs.

My research investigates collagen-binding receptors on breast cancer cells as potential biomarkers to distinguish harmless early-stage tumours from aggressive ones. Using genetically matched 3D cancer models, the project identifies how receptor activity affects invasion and collagen organization, aiming to reduce overtreatment and support clearer clinical decisions for early breast cancer patients.

This research focuses on developing reliable blood-based biomarkers to evaluate new treatments for hereditary frontotemporal dementia. By identifying an imbalance between two key molecules, progranulin and prosaposin, the work aims to provide accurate measures of treatment effectiveness and bring hope to families carrying this devastating genetic condition

My research uses spatial RNA sequencing to map where genes are expressed within tissues affected by chronic inflammatory diseases. By capturing genetic information with precise spatial coordinates, it creates an atlas of disease-driving genes. This deeper understanding may reveal new biomarkers and therapeutic targets, enabling future treatments beyond symptom management.